US EditionPublished • loading... • Updated
Trump announces reforms to accelerate access to psychedelic drug treatments
The order directs $50 million for state research programs and tells federal agencies to speed trials for drugs still classified as Schedule I.
- On Saturday, April 18, 2026, President Donald Trump signed an executive order directing federal agencies to expedite research on psychedelic drugs, including ibogaine, and committed $50 million to federal research.
- Health Secretary Robert F. Kennedy Jr. and podcaster Joe Rogan joined Trump at the Oval Office, highlighting veteran mental health crises; Kennedy noted thousands of veterans travel to Mexico for treatments due to domestic restrictions.
- Trump cited a 2024 Stanford University study showing 30 special operations veterans experienced an 80% to 90% reduction in depression and anxiety symptoms within one month, though critics warn ibogaine remains classified as Schedule I with known cardiotoxicity risks.
- FDA Commissioner Marty Makary announced the agency will issue national priority vouchers next week to accelerate reviews, targeting approvals within weeks, while opening a Right-to-Try pathway for terminally ill patients.
- While ibogaine remains Schedule I, the order signals a shift from underground use to federal acknowledgment, potentially encouraging states to fund university research programs and reshaping access for veterans long-term.
Insights by Ground AI
Podcasts & Opinions
180 Articles
180 Articles
With Executive Order, Trump Accelerates Psychedelic Research, Joking: ‘Can I Have Some?’
‘In many cases, these experimental treatments have shown life-changing potential for those suffering from severe mental illness and depression, including our cherished veterans,’ the president says.
·New York, United States
Read Full Article
The president of the United States, Donald Trump, ordered this Saturday by decree to speed up the review of some psychedelic drugs for medicinal purposes, in what could be a paradigm shift in the use of these drugs.It is ibogaine, which remains classified as an illegal substance of ‘high risk’ under the most restrictive category of the federal government.But the Trump administration took concrete steps to relax restrictions and promote research …
·Buenos Aires, Argentina
Read Full ArticleCoverage Details
Total News Sources180
Leaning Left30Leaning Right31Center88Last UpdatedBias Distribution59% Center
Bias Distribution
- 59% of the sources are Center
59% Center
L 20%
C 59%
R 21%
Factuality
To view factuality data please Upgrade to Premium
